Article
Hematology
Ja Min Byun, Dong-Yeop Shin, Youngil Koh, Junshik Hong, Inho Kim, Sung-Soo Yoon, Soo-Mee Bang, Jeong-Ok Lee
Summary: This study retrospectively examined the outcomes of 106 AML patients in CR1 undergoing AlloSCT with or without consolidation chemotherapy. Results showed that consolidation chemotherapy prior to AlloSCT with RIC conditioning did not negatively impact the outcomes, with longer RFS and overall survival in the consolidation group. Additionally, consolidation did not affect engraftment rates but may lead to a higher degree of chronic GVHD.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2021)
Review
Oncology
Shukaib Arslan, Vinod Pullarkat, Ibrahim Aldoss
Summary: The treatment paradigm for ALL in adults, particularly the role of alloHCT, needs to be reevaluated with individualized decision-making. Advances in treatment options require consideration of various factors for complex decision-making.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
David I. Marks, Anna Castleton, Eduardo Olavarria, Maria Gilleece, Adele Fielding, George Mikhaeel, Matthew Beasley, Patricia Diez, Aimee Jackson, Andrea Hodgkinson, Mohamed Elhanied, Ronjon Chakraverty
Summary: This study examines the usage of T-cell depleted, reduced intensity conditioning (RIC) approach to haematopoietic cell transplantation (HCT) in adult patients with acute lymphoblastic leukaemia (ALL). The results show encouraging survival rates but high relapse rates, suggesting the need for more powerful conditioning approaches.
Article
Hematology
Tommy Alfaro Moya, Jonas Mattsson, Mats Remberger, Jeffrey H. Lipton, Dennis D. Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun D. Law, Armin Gerbitz, Ivan Pasic, Igor Novitzky-Basso, Fotios V. Michelis
Summary: This retrospective analysis compared the outcomes of myeloablative (MAC) and reduced intensity conditioning (RIC) in allogenic hematopoietic cell transplantation (alloHCT) for acute myeloid leukemia (AML) in complete remission (CR). The results showed differences in nonrelapse mortality, cumulative incidence of relapse, and overall survival between the two treatment methods. However, in the subgroup analysis of matched related donor transplants, MAC was associated with superior survival. Overall, the outcomes of MAC and RIC were similar in this cohort of predominantly in vivo T-cell depleted patients.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Iman Sidhom, Khaled Shaaban, Sarah H. Youssef, Nesreen Ali, Seham Gohar, Wafaa M. Rashed, Mai Mehanna, Sherine Salem, Sonya Soliman, Dina Yassin, Emad Mansour, Elaine Coustan-Smith, Raul C. Ribeiro, Gaston K. Rivera
Summary: Improved outcomes in children with very-low-risk (VLR) ALL can be achieved with low-intensity therapy based on presenting features and minimal residual disease (MRD) levels. However, patients with MRD levels between 0.001% and <0.01% during early remission induction may have a higher risk of relapse compared to those with undetectable residual leukemia.
Article
Oncology
Dipenkumar Modi, Samer Alkassis, Seongho Kim, Andrew Kin, Abhinav Deol, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti
Summary: We retrospectively evaluated allogeneic stem cell transplant (alloSCT) outcomes of 86 adult ALL patients in complete remission (CR) who received TBI-containing reduced intensity (RIC) and myeloablative conditioning (MAC). The study found no significant difference in survival rate between the RIC and MAC groups, but the MAC group had a lower relapse rate.
LEUKEMIA & LYMPHOMA
(2023)
Article
Hematology
Riccardo Masetti, Edoardo Muratore, Davide Gori, Arcangelo Prete, Franco Locatelli
Summary: The selection of allo-HSCT for pediatric patients with AML in CR1 is still debated. This meta-analysis found that allo-HSCT improved overall survival and disease-free survival compared to chemotherapy in high-risk pediatric AML patients in CR1, but with an increased relapse rate. Sensitivity analysis confirmed the benefit of allo-HSCT on overall survival. Further research should focus on individualizing allo-HSCT indications based on molecular stratification and MRD monitoring.
ANNALS OF HEMATOLOGY
(2022)
Article
Cell & Tissue Engineering
Guangyu Sun, Baolin Tang, Kaidi Song, Yue Wu, Meijuan Tu, Xiang Wan, Wen Yao, Liangquan Geng, Ping Qiang, Xiaoyu Zhu
Summary: This study compared the outcomes of UCBT and MST in the treatment of adult B-ALL patients. The results showed that UCBT had slower hematopoietic recovery but lower incidence of extensive cGVHD. The NRM, relapse, DFS, and GRFS were comparable between MST and UCBT recipients, but UCBT showed better OS for patients with long-term survival.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Hematology
Hisashi Ishida, Yuki Arakawa, Daiichiro Hasegawa, Ikuya Usami, Yoshiko Hashii, Yasuyuki Arai, Satoshi Nishiwaki, Dai Keino, Keisuke Kato, Maho Sato, Nao Yoshida, Yukiyasu Ozawa, Keiko Okada, Moe Hidaka, Yuki Yuza, Masatsugu Tanaka, Kenichiro Watanabe, Junko Takita, Yoshiyuki Kosaka, Naoto Fujita, Junji Tanaka, Atsushi Sato, Yoshiko Atsuta, Toshihiko Imamura
Summary: In this study, data of Ph+ALL patients receiving HSCT in Japan were retrospectively collected, showing that RIC regimen in HSCT for younger patients had comparable long-term leukemia-free survival rates to the traditional MAC regimen, with RIC being an independent favorable prognostic factor.
ANNALS OF HEMATOLOGY
(2023)
Article
Immunology
Aniko Sijs-Szabo, Avinash G. Dinmohamed, Jurjen Versluis, Bronno van der Holt, Mar Bellido, Mette D. Hazenberg, Michel van Gelder, Nicolaas P. M. Schaap, Ellen Meijer, Lotte E. van der Wagen, Constantijn J. M. Halkes, Anita W. Rijneveld, Jan J. Cornelissen
Summary: In this retrospective study, RIC-alloHSCT was compared with MAC-alloHSCT in older adult patients with acute lymphoblastic leukemia. The results showed that RIC-alloHSCT had lower nonrelapse mortality but a significantly higher relapse rate compared to MAC-alloHSCT. These findings suggest that MAC-alloHSCT may be a more effective consolidation therapy for reducing relapse.
Article
Biophysics
Raynier Devillier, Jacques-Emmanuel Galimard, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Jiri Pavlu, Luca Castagna, Gerard Socie, Yves Chalandon, Massimo Martino, Friedrich Stolzel, Gesine Bug, Benedetto Bruno, Radovan Vrhovac, Amandine Charbonnier, Attilio Olivieri, Jacques-Olivier Bay, Herrera Arroyo, Ibrahim Yakoub-Agha, Daniele Avenoso, Andreas Neubauer, Stephanie Nguyen, Edouard Forcade, Eolia Brissot, Bipin Savani, Arnon Nagler, Mohamad Mohty
Summary: The optimal conditioning regimen prior to haploidentical stem cell transplantation for acute myeloid leukemia remains uncertain. In younger patients, intensifying the conditioning from CyFluTBI to TBF may reduce relapse risk, while in older patients, the conditioning regimen does not significantly influence survival but can lower the risk of non-relapse mortality.
BONE MARROW TRANSPLANTATION
(2022)
Article
Hematology
Armin Ghobadi, Michael Slade, Hagop Kantarjian, Julio Alvarenga, Ibrahim Aldoss, Kahee A. Mohammed, Elias Jabbour, Rawan Faramand, Bijal Shah, Frederick Locke, Warren Fingrut, Jae H. Park, Nicholas J. Short, Feng Gao, Geoffrey L. Uy, Peter Westervelt, John F. DiPersio, Richard E. Champlin, Monzr M. Al Malki, Farhad Ravandi, Partow Kebriaei
Summary: Adult patients with Ph+ ALL who achieved CMR within 90 days of starting treatment did not derive a survival benefit from allo-HCT in CR1, according to this retrospective study.
Article
Immunology
Lu Han, Ran Zhao, Jingyi Yang, Yingling Zu, Yanyan Liu, Jian Zhou, Linlin Li, Zhenghua Huang, Jishuai Zhang, Quanli Gao, Yongping Song, Keshu Zhou
Summary: This article reports a case of successful allogeneic hematopoietic stem cell transplantation (allo-HSCT) using CAR-T cell therapy as a conditioning regimen for a relapsed/refractory acute lymphoblastic leukemia patient. Despite the occurrence of acute graft versus host disease, the patient remained in complete remission.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Yu Akahoshi, Hideki Nakasone, Katsuto Takenaka, Satoshi Yamasaki, Momoko Nakamura, Noriko Doki, Masatsugu Tanaka, Yukiyasu Ozawa, Naoyuki Uchida, Takahide Ara, Hirohisa Nakamae, Shuichi Ota, Makoto Onizuka, Shingo Yano, Junji Tanaka, Takahiro Fukuda, Yoshinobu Kanda, Yoshiko Atsuta, Shinichi Kako, Masamitsu Yanada, Yasuyuki Arai
Summary: A nationwide retrospective study revealed that cytomegalovirus reactivation (CMVR) is associated with a lower relapse risk in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients after allogeneic hematopoietic cell transplantation (HCT). This finding suggests important implications for CMV prophylaxis strategies after HCT.
Article
Hematology
Shlomo Elias, Samantha Brown, Sean M. Devlin, Juliet N. Barker, Christina Cho, David J. Chung, Parastoo B. Dahi, Sergio Giralt, Boglarka Gyurkocza, Ann A. Jakubowski, Oscar B. Lahoud, Heather Landau, Richard J. Lin, Esperanza B. Papadopoulos, Ioannis Politikos, Doris M. Ponce, Michael Scordo, Brian C. Shaffer, Gunjan L. Shah, Roni Tamari, James W. Young, Miguel-Angel Perales, Roni Shouval
Summary: Comorbidity assessment is important before allogeneic haematopoietic cell transplantation (allo-HCT) to estimate non-relapse mortality (NRM) risk. The Simplified Comorbidity Index (SCI), which includes a small number of comorbidities and older age, has been shown to predict NRM. In this study, we validated the SCI in patients receiving reduced-intensity conditioning followed by allo-HCT from HLA-matched donors. Higher SCI scores were associated with increased NRM risk and reduced overall survival. These findings suggest that the SCI is a reliable tool for risk stratification in allo-HCT candidates.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Jae-Ho Yoon, Young-Woo Jeon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Jong-Wook Lee, Woo-Sung Min, Seok-Goo Cho
HEMATOLOGICAL ONCOLOGY
(2017)
Article
Gastroenterology & Hepatology
Ji Won Han, Hyun Yang, Hae Lim Lee, Si Hyun Bae, Jong Young Choi, Jong-Wook Lee, Hee Je Kim, Seok Lee, Seok Goo Cho, Chang Ki Min, Dong Wook Kim, Seung Kew Yoon
HEPATOLOGY RESEARCH
(2016)
Article
Hematology
Nayoun Kim, Seok-Goo Cho
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2016)
Article
Hematology
Nayoun Kim, Hyun-Jung Sohn, Joo Hyun Oh, Young-Woo Jeon, Hyun-Joo Lee, Hyun-Il Cho, Byung Ha Chung, Chul-Woo Yang, Tai-Gyu Kim, Seok-Goo Cho
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2018)
Article
Biophysics
John Kuruvilla, Cheng-Hwai Tzeng, Seok-Goo Cho, Seok Jin Kim, Jih-Luh Tang, Yaming Su, Jingyang Wu, Rita Vargo, Peter Cheverton
BONE MARROW TRANSPLANTATION
(2019)
Article
Hematology
Young-Woo Jeon, Joo-Hyun O, Kyung-Sin Park, Gi June Min, Sung-Soo Park, Jae-Ho Yoon, Ki-Seong Eom, Chang-Ki Min, Seok-Goo Cho
BRITISH JOURNAL OF HAEMATOLOGY
(2020)
Article
Biophysics
Jae-Ho Yoon, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Hee-Je Kim, Seok Lee
Summary: This study identified the incidence and survival outcome of hepatic sinusoidal obstruction syndrome/veno-occlusive disease (VOD/SOS) after hematopoietic cell transplantation (HCT) under a strategy of prophylactic ursodiol and intravenous heparin or prostaglandin E1. The overall incidence of hepatic VOD/SOS was 3.4% after allogeneic-HCT, with varying survival rates based on severity grades. Factors affecting development of VOD/SOS included disease risk index, gender, donor type, and busulfex dosage. Allogeneic-HCT using ursodiol and intravenous prophylaxis was considered safe, but early intervention for high-risk VOD/SOS patients is crucial.
BONE MARROW TRANSPLANTATION
(2021)
Article
Oncology
Sung-Yong Kim, Won-Sik Lee, Sung Yong Oh, Deok-Hwan Yang, Hyo Jung Kim, Seong Kyu Park, Jae Wook Yang, Suk-Woo Yang, Seok-Goo Cho
Summary: In this study, the long-term efficacy of rituximab, cyclophosphamide, doxorubicin, and prednisolone (R-CVP) chemoimmunotherapy in limited-stage ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML) patients was investigated. The results showed a high response rate and a significant risk of late relapse. The study suggests that clinical trials for limited-stage OAML patients should have a long-term observation period and consider sequential or combination treatment to reduce the risk of delayed relapse.
Article
Hematology
Hee Won Park, Gi June Min, Tong Yoon Kim, Seok-Goo Cho
Summary: This case report describes a 21-year-old man who developed secondary HLH following the second dose of the BNT162b2 vaccine. He was treated with steroid pulse therapy without any other complications.
ACTA HAEMATOLOGICA
(2022)
Article
Oncology
Gi-June Min, Tong Yoon Kim, Young-Woo Jeon, Joo O. Hyun, Byung-Ock Choi, Gyeongsin Park, Young-Hoon Park, Seok-Goo Cho
Summary: This study aimed to identify factors indicative of PIOL, describe treatment outcomes, and determine modalities to prevent relapse. The study found that ophthalmologic and central nervous system relapse were common in PIOL patients regardless of the treatment modalities. Therefore, diagnosis should be based on clinical signs and assisted by vitrectomy, cytologic, molecular, and cytokine studies.
Article
Hematology
Gi-June Min, Donghoon Kang, Han Hee Lee, Seung-Jun Kim, Tong Yoon Kim, Young-Woo Jeon, Joo Hyun, Byung-Ock Choi, Gyeongsin Park, Seok-Goo Cho
Summary: This study evaluated the real-world clinical outcomes of different therapeutic modalities for gastric MALT lymphoma and analyzed factors affecting survival outcomes. Helicobacter pylori eradication was found to be effective in achieving complete remission in localized HPI-positive patients. Poor response to eradication was associated with lesions in specific locations and invasion depth, while HPI negativity correlated with poor progression-free survival. HPI eradication should be the first-line treatment for localized HPI-positive gastric MALT lymphoma, while radiotherapy is recommended for HPI-negative patients or when eradication fails.
ANNALS OF HEMATOLOGY
(2023)
Letter
Medical Laboratory Technology
Hyunhye Kang, Seok-Goo Cho, Eun-Jee Oh
ANNALS OF LABORATORY MEDICINE
(2023)
Article
Multidisciplinary Sciences
Rae-Young Kim, Jae Hyun Park, Mirinae Kim, Young-Geun Park, Seok-Goo Cho, Young-Hoon Park
Summary: The study evaluated changes in choroidal vascular structure and aqueous cytokine levels in eyes with vitreoretinal lymphoma (VRL) after treatment with intravitreal methotrexate (MTX). Results showed improvements in choroidal structure and cytokine levels after treatment, indicating potential factors influencing treatment outcomes for VRL patients.
Letter
Hematology
Frits van Rhee, Jean-Francois Rossi, David Simpson, Alexander Fossa, Angela Dispenzieri, John Kuruvilla, Yeow Tee Goh, Seok-Goo Cho, Marcelo Capra, Ting Liu, Corey Casper, James Cavet, Raymond S. Wong
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Medicine, General & Internal
Young-Woo Jeon, Hee-Jung Yang, Byung-Ock Choi, Seung-Eun Jung, Kyung-Sin Park, O. Joo-Hyun, Suk-Woo Yang, Seok-Goo Cho